An artificial intron containing the insect cell polyhedrin (polh) promoter was designed, constructed, and inserted into the adeno-associated virus (AAV) Rep and Cap coding sequences to express the Rep and Cap proteins, respectively. The artificial intron was spliced out and full-length Rep78 or VP1 proteins were expressed from the insect promoters located upstream of their respective AUG start codons. The polh promoter located inside the artificial intron was functional, expressed the Rep52 or VP2/VP3 proteins located downstream of the artificial intron, and overlapped with the Rep78 or VP1 proteins. This is the first report that an artificial intron containing an insect cell promoter can be inserted into a coding sequence to express genes with overlapping open-reading frames (ORFs). A method was also established for AAV vector production in insect cells with these intron-containing Rep and Cap coding sequences, and the vectors produced thereby were infectious. These intron-containing AAV Rep and Cap coding sequences were very stable in recombinant baculoviruses and showed no apparent loss of protein expression even after five consecutive amplifications of the plaque-purified recombinant baculoviruses. This newly established AAV production method should prove to be a useful tool for large-scale AAV vector production.
IntroductIon
Genes containing overlapping open-reading frames (ORFs) are known to exist in mammalian genomes. In some cases, such genes contain an intron having a promoter that supports transcription of an ORF. 1, 2 However, no insect gene, either naturally occurring or artificial, has been reported that encodes multiple ORFs and contains a promoter within an intron. Although it has been reported that the immediate-early IE-1 gene of Autographa californica nuclear polyhedrosis virus comprises a functional intron that can be spliced in insect cells, 3 none of the current baculovirusbased insect cell expression systems employs any intron for protein expression.
In recent years, adeno-associated virus (AAV) has emerged as a preferred viral vector for gene therapy because of its ability to infect efficiently both nondividing and dividing cells, integrate into a single chromosomal site in the human genome, and pose a relatively low pathogenic risk to humans. [4] [5] [6] [7] In view of these advantages, recombinant AAV has been used in gene therapy clinical trials for hemophilia B, malignant melanoma, cystic fibrosis, and other diseases. 6, [8] [9] [10] The most commonly used protocol utilizes transient transfection of production plasmids into adherent HEK293 cells to produce AAV vectors. Several alternative production methods involving packaging cell lines combined with helper viruses have been developed to address the problem of large-scale AAV vector production. [11] [12] [13] Recently, there have been reports that HEK293 cells were adapted to suspension culture for large-scale AAV vector production. [14] [15] [16] Whereas these methods represent some significant progress, further improvements are needed to meet the challenge of large-scale AAV vector production.
Since Urabe et al. 17 first reported the use of a baculovirusbased expression system for AAV production in insect cells, this methodology has steadily gained more attention. Several research groups have reported the use of insect cells to produce AAV vectors. [18] [19] [20] [21] [22] [23] [24] Because AAV intron and promoters do not function properly in insect cells, most of these studies used two separate Rep coding sequences in two expression cassettes, one for Rep78 and the other for Rep52 in a palindromic head-to-tail arrangement. In addition, these studies used the Cap coding sequence with its VP1 start codon mutated (from AUG to ACG). Given the large homologous repeats of the Rep78 and Rep52, it has been reported that the recombinant baculovirus harboring this large Rep homologous repeat sequence was unstable, and the Rep protein expression was lost after several passages. 20 It has also been reported that AAV vectors produced in insect cells with the AUG-to-ACG mutation of the VP1 start codon are less infectious because of the relatively poor expression of VP1 protein. Several modifications have been made for improving the infectivity of AAV vectors, including phospholipase A2 domain (PLA2) swapping, supplementation of VP1, and optimization of the VP1 start codon and its surrounding nucleotide sequence. 20, 21, 24 In the present study, a novel artificial intron was designed, constructed, and inserted into both the Rep and Cap coding sequences in order to express the Rep and Cap proteins. A single Rep coding sequence containing this artificial intron expressed both the Rep78 and the Rep52 proteins. This made it possible to avoid the use of large homologous Rep repeats, thereby giving greater stability to the recombinant baculovirus harboring the Rep coding sequence. Further, the authentic VP1 start codon AUG was preserved because a single intron-containing Cap coding sequence could express all three Cap proteins (VP1, VP2, and VP3). Finally, a method of AAV vector production in insect cells with these intron-containing Rep and Cap coding sequences was established. The yield of AAV vectors was comparable to those obtained by the earlier method, and the AAV vectors were more infectious than those produced by means of the start codonmutated VP1 coding sequence. results the artificial intron is functional in insect cells and expresses overlapping AAV type 2 rep78 and rep52 proteins In mammalian cells, the four Rep proteins of AAV are encoded by multiple transcripts from a single reading frame (Figure 1a) . In order to express both Rep78 and Rep52 in insect cells from a single coding sequence, an artificial intron containing the polh promoter was constructed with an intron splice-acceptor as described by Chisholm and Henner 3 and inserted into the p19 promoter region between nucleotides 850 and 851 (nucleotide numbers follow the standard numbering of the AAV2 genome as in GenBank accession no. AF043303). Recombinant baculovirus harboring this introncontaining Rep coding sequence was generated. The complete sequence of the artificial intron containing the polh promoter is shown in Figure 1b , and the recombinant baculovirus Bac-inRep is shown in Figure 1c . Sf9 cells were infected by Bac-inRep to express Rep78 and Rep52 proteins. Figure 2a shows that both the Rep78 and Rep52 were expressed (lanes 1 and 2), thereby indicating that the artificial intron was functional in the insect cells.
AAV type 2 VP1, VP2, and VP3 proteins can be expressed from a single cap coding sequence containing the artificial intron In order to preserve the authentic AUG start codon and express high levels of VP1, VP2, and VP3 proteins such that AAV vectors could be packaged in insect cells, the artificial intron was cloned into the Cap coding sequence between nucleotides 2,227 and 2,228 (standard numbering of the AAV2 genome), and the recombinant baculovirus Bac-inCap was generated (Figure 1d) . This was used for infecting Sf9 cells to express the Cap proteins. Cell lysates were prepared and Western blot was performed. The results, shown in Figure 2a , demonstrate that all three Cap proteins, VP1, VP2, and VP3 were expressed (lanes 3 and 4), again indicating the efficient splicing of the artificial intron to form a mature VP1 messenger RNA, and also the transcription of messenger RNA for VP2/VP3 expression by the polh promoter located inside the artificial intron. It is interesting to note that the expression levels of VP1 and VP2 proteins were nearly as high as that of VP3, thereby indicating that the VP1 protein expression was not significantly affected by the insertion of the artificial intron.
the artificial intron also functions in the capsid genes of other AAV serotypes In addition to being functional in an AAV2 setting, the artificial intron also worked well in other AAV serotypes. This cassette was inserted into the AAV type 1 Cap coding sequence between nucleotides 2,247 and 2,248 (GenBank accession no. NC_002077), into the AAV type 6 Cap coding sequence between nucleotides 2,232 © The American Society of Gene Therapy and 2,233 (GenBank accession no. NC_001862), and into the AAV type 8 Cap coding sequence between nucleotides 2,145 and 2,146 (GenBank accession no. NC_006261). Recombinant baculoviruses Bac-inCap1, Bac-inCap6, and Bac-inCap8, respectively, were generated. Sf9 cells were infected by these recombinant baculoviruses for 3 days and cell pellets were harvested for Western blot analysis (Figure 2b) . The artificial intron worked in all the AAV types tested for expression of the VP1, VP2, and VP3 proteins. Further, all Cap coding sequences containing the artificial intron expressed high levels of VP1 proteins.
High titers of AAV vectors can be produced by means of the artificial intron-containing AAV rep and cap coding sequences
After expression of AAV Rep and Cap proteins, experiments were performed to test AAV packaging with these intron-containing Rep and Cap coding sequences. In order to package AAV2-GFP (or AAV2-RFP) vectors, recombinant baculoviruses Bac-inRep, Bac-inCap, and Bac-GFP (or Bac-RFP) were used. In order to package AAV6 or AAV8 vectors, Bac-inCap was simply substituted with Bac-inCap6 or Bac-inCap8 recombinant baculoviruses, respectively. Sf9 cells were infected for 3 days and cell pellets were collected. AAV vector purification was performed as described in Materials and Methods. AAV vectors were quantified using realtime quantitative polymerase chain reaction (PCR). The recombinant baculoviruses harboring the artificial intron-containing Rep and Cap sequences not only expressed higher levels of VP1 proteins, but also produced high titers of AAV vectors, with the yields being comparable to those described by Urabe et al. 17 ( Table 1) . In order to streamline the production system further, the artificial intron-containing Rep and Cap coding sequences were cloned together and a recombinant baculovirus, Bac-inRep-inCap, was generated to express Rep78/Rep52 and VP1/VP2/VP3 proteins. Double infection of Sf9 cells with Bac-inRep-inCap and Bac-GFP also produced high titers of AAV type 2 vectors ( Table 1) .
More VP1 proteins were packaged in the virions when the artificial intron-containing cap coding sequence was used Since the intron-containing Cap coding sequence expressed more VP1 proteins, it would be expected that more VP1 proteins could be packaged into the virions. Several lots of AAV vectors were prepared with the recombinant baculoviruses that carry Rep and Cap coding sequences containing the artificial intron, and they were compared with AAV vectors produced in insect cells with the older vector with the mutated start codon (from AUG to ACG) Cap coding sequence as described by Urabe et al. 17 After infection of Sf9 cells for 3 days, cell pellets were harvested. A small portion of each pellet was used to prepare cell lysates for Western blot analysis and the rest was used for vector purification using CsCl ultracentrifugation as described in Materials and Methods. Higher levels of VP1 protein were detected in the Sf9 cells infected with the artificial intron-containing Rep and Cap recombinant baculoviruses ( Figure 3a , lanes 2 and 4) than in those infected with the artificial intron-less Rep and start codon-mutated Cap recombinant baculoviruses (Figure 3a , lanes 1 and 3). These results demonstrate that, whereas the VP1 expression level was sub-optimal from start codon-mutated Cap coding sequence, robust expression of VP1 was obtained from the artificial intron-containing Cap coding sequence. In the CsCl-purified AAV vector samples, more VP1 was packaged into the AAV virions using the recombinant baculoviruses carrying the artificial intron-containing Rep and Cap coding sequences than by using those carrying artificial intron-less Rep and start codon-mutated Cap coding sequences (Figure 3a , compare lanes 5 and 7 with 6 and 8). The amount of VP1 packaged into the virions by the artificial intron-containing Rep and Cap coding sequences (Figure 3a , lanes 6 and 8) was essentially equivalent to the level in virions produced in HEK293 cells (Figure 3a, lane 9 ). In the case of AAV type 6 or AAV type 8, there was also more VP1 present in the lysates when using recombinant baculoviruses carrying the artificial intron-containing AAV type 6 or AAV type 8 Cap coding sequences (Figure 3b , lanes 2 and 4) than when using those carrying artificial intron-less Rep and start codon-mutated Cap coding sequences (Figure 3b, lanes  1 and 3) . In the purified AAV type 6 and AAV type 8 virions, there was also more VP1 packaged (Figure 3b, lanes 6 and 8) when the artificial intron-containing Rep and Cap coding sequences were used in the vector production.
AAV vectors produced in insect cells with the artificial intron-containing rep and cap coding sequences are infectious
In order to determine whether the AAV vectors produced in insect cells with the artificial intron-containing Rep and Cap coding sequences were more infectious than those produced with the intron-less Rep and start codon-mutated Cap coding sequences, cell-based assays were performed. Because AAV8 does not infect cultured cells efficiently, only AAV2 and AAV6 vectors were tested. Serially diluted AAV vectors were used for transducing HepG2 cells for 48 hours, and green fluorescent protein (GFP) expression was recorded by fluorescence microscopy. The numbers of GFP-expressing cells were scored and the mean relative infectivity was calculated from three sets of independent experiments. AAV2 produced using the new method was more infectious than that produced using the VP1 start codon-mutated (AUG to ACG) Cap coding sequence (Figure 4a) . In fact, the former (AUGVP1) was about two times as infectious as the latter (ACGVP1). Similar results were observed in the case of AAV6, with the vectors produced by start codon-mutated VP1 coding sequence being less infectious because of the lower level of VP1 proteins packaged in the vectors (Figure 4b ).
Artificial intron-containing rep and cap coding sequences are very stable in baculoviruses
In order to determine whether the artificial intron-containing Rep and Cap coding sequences were stable in baculoviruses, both recombinant baculoviruses were plaque-purified and each plaque was serially passaged five times. Cell pellets were collected and lysates were prepared from each passage. The expressions of Rep and Cap proteins were determined by Western blot. All 12 artificial intron-containing Rep clones appeared to be very stable and no apparent loss of Rep protein expression was observed even after five consecutive passages (Figure 5a) . When the Rep protein levels were compared from passages 1-5, there was shown to be a slight decrease in the Rep protein expression in passage 3 because of an insufficient amount of the recombinant baculoviruses used in the experiment. When infection time was increased from 2 to 3 days to obtain better infection, the Rep protein expression level increased, thereby indicating that the Rep sequence was not lost (Figure 5b) . All six artificial intron-containing Cap clones also appeared to be very stable. There was no apparent loss of Cap protein expression even after five consecutive passages (Figure 5c and d) .
dIscussIon
Intron-splicing is a ubiquitous mechanism of regulation of gene expression in eukaryotes, from yeast to human. 25, 26 Although Chisholm and Henner first reported that the immediate-early IE-1 gene of A. californica nuclear polyhedrosis virus comprises a functional intron that can be spliced in insect cells, 3 none of the [Q7] current baculovirus-based expression systems employs an intron to regulate protein expression. In fact, Jeang et al. 27 reported that only the small T-antigen, but little or no large T-antigen, was expressed in insect cells when the intron-containing simian virus 40 T-antigen fragment was introduced into insect cells, thereby indicating that the intron-splicing machinery of insect cells cannot properly recognize and splice the simian virus 40 intron to form a mature messenger RNA for large T-antigen expression.
In mammalian cells, the AAV genome encodes four Rep proteins through multiple transcripts from a single ORF (Figure 1a) . Promoters at map units 5 and 19 regulate transcription of the Rep ORF. Because the p19 promoter is located inside the Rep78 coding region, any attempt to modify the p19 promoter into an insect cell-compatible promoter will change the composition, and thus the function, of the Rep78 protein. The current study presents a novel method of using the artificial intron to express both the Rep78 and Rep52 proteins in insect cells from a single Rep coding sequence, while not disrupting the Rep78 coding region. This artificial intron worked not only for the Rep coding sequence of AAV2, but also for the Cap coding sequences of AAV1, 2, 6, and 8 types, thereby indicating the universal application of this artificial intron in insect cells. This is the first report that a promoter-containing artificial intron can be functional in insect cells, and that overlapping proteins such as the Rep78 and Rep52 can be expressed using this uniquely designed expression cassette instead of two separate Rep coding sequences. This discovery is significant because it can be used for expressing many other overlapping genes in insect cells without the need to separate these overlapping genes into multiple baculoviruses. In addition, this unique artificial intron can comprise different gene expression regulatory elements, such as DNA-binding elements for activators or repressors, so that the downstream gene(s) can be regulated without disrupting the upstream gene(s).
The parvovirus VP1 protein plays a critical role in the infectivity of the virus because it contains a phospholipase A2 domain (PLA2). 28 Several research groups have reported that AAV vectors produced in insect cells are less infective than those produced in 293 cells, and that the cause of this decreased infectivity was the decreased expression level of VP1 protein. When VP1 protein level was increased by various modifications such as phospholipase A2 domain swapping or optimization of the start codon of VP1 and its surrounding nucleotide sequence, the infectivity of the vectors was improved. 20, 21, 24 In this study, a specifically designed artificial intron-containing expression cassette expressed high levels of VP1, VP2, and VP3 proteins in insect cells in all AAV serotypes tested (Figure 2a and b) . When AAV vectors were produced in insect cells using this method, the infectivity of the AAV vectors was improved because of the higher level of VP1 expression (Figure 4a and b) , thereby confirming the observation of other researchers that the lower infectivity of AAV vectors produced in insect cells was caused by the sub-optimal expression of VP1 protein. It is worth noting that, even though more VP1 proteins were expressed from the recombinant baculovirus harboring the artificial intron-containing Cap coding sequence, there seems to be no apparent negative effect on AAV vector packaging, given that the AAV yields were similar to those observed with the recombinant baculovirus harboring the artificial intron-less Cap coding sequence, which expresses less VP1 protein ( Table 1) . AAV Rep proteins have been known to inhibit the replication of other viruses such as adenovirus, simian virus 40, herpes simplex virus, human papilloma virus, and human immunodeficiency virus. [29] [30] [31] [32] [33] [34] Urabe et al. reported that the titers of recombinant baculoviruses carrying either the AAV2 or AAV5 Rep gene, driven by truncated promoter for the immediate-early 1 (IE-1) gene of Orgyia pseudotsugata nuclear polyhedrosis virus, were generally lower than those of other recombinant baculoviruses that carry GFP or Cap genes, 24 thereby implying the possible inhibition of baculovirus replication by AAV Rep proteins. In the present study, no significant difference in titer was found between baculovirus with the artificial intron-containing Rep coding sequence and the other baculoviruses that carry GFP or Cap genes (data not shown). This observation indicates that the p10 promoter-driven Rep78 and polh promoter-driven Rep52 have limited inhibitive effects on baculovirus replication, possibly because of their delayed expression in the baculovirus life cycle. In fact, Palombo et al. reported the generation of recombinant baculovirus expressing AAV2 Rep78 protein under the control of polh promoter and observed no apparent inhibitory effects on baculovirus replication and propagation. 35 It has been reported that a reduction in Rep gene expression in mammalian cells is associated with an increase in recombinant AAV yield. [36] [37] [38] Urabe et al. used truncated forms of IE-1 promoter or p10 promoter to decrease the expression level of Rep78, on the basis of the assumption that high levels of Rep78 protein expression might negatively affect the AAV production yields in insect cells. 17, 24 In this study, the complete p10 promoter was used for driving the expression of Rep78 in insect cells, and high levels of Rep78 protein were expressed (Figure 2a, lanes 1 and 2) . When this Rep-containing recombinant baculovirus was used for producing AAV vectors in triple-or double-infection schemes, AAV vector yields were similar, if not higher, than when a baculovirus carrying Rep sequence under the control of truncated IE-1 promoter was used ( Table 1 ). This result demonstrates that a high level of Rep78 protein expression does not negatively affect the AAV production yields in insect cells, and indicates that insect cells are more tolerant of Rep78 protein in AAV packaging than mammalian cells are.
It is known that homologous repeats of DNA sequence are prone to deletion by homologous recombination. 39, 40 The pioneering work of Urabe et al. in producing AAV vectors in insect cells used a recombinant baculovirus that carries the Rep78 and Rep52 coding sequences in a palindromic head-to-tail configuration. 17 This recombinant baculovirus has been reported to be unstable and Rep protein expression was lost after several passages. To alleviate this problem, Kohlbrenner et al. 20 separated the Rep78 and Rep52 coding sequences into two separate recombinant baculoviruses and showed that they were more stable. The current paper presents a novel method to achieve expressions of both Rep78 and Rep52 in a single coding sequence while avoiding the use of large homologous repeats. The recombinant baculovirus carrying this artificial introncontaining Rep coding sequence was very stable, and showed no apparent loss of Rep protein expression even after five consecutive passages (Figure 5a and b) . Similarly, the recombinant baculovirus carrying the artificial intron-containing Cap coding sequence was also very stable, and no apparent loss of VP protein expression was observed even after five consecutive passages (Figure 5c and d) .
Stability of the recombinant baculoviruses is critical for large-scale GMP production of clinical materials, because multiple amplifications of the seed baculoviruses are required. The method presented here essentially solves the stability problem.
In summary, this study presents a novel method for achieving the expression of multiple overlapping ORFs in insect cells, using the unique design of an artificial intron that contains an insect cellcompatible promoter. The study further demonstrates that the AAV vectors produced using the recombinant baculoviruses carrying the artificial intron-containing AAV Rep or Cap coding sequences were more infectious than those produced using the method reported earlier, because of the increased expression of VP1 protein. This novel method of producing AAV vectors should prove to be a useful tool for large-scale AAV vector production. Furthermore, the unique artificial intron offers a new way to study the mechanisms of intron-splicing and gene expression regulation in insect cells.
MAterIAls And MetHods
Plasmid construction. The plasmid pAAV-RC (Stratagene, La Jolla, CA) was first digested with HindIII and SacI to isolate the backbone fragment [6,259 base pairs (bp)]. Then the pAAV-RC was digested with DrdI and HindIII to isolate a 977-bp fragment. Finally, 12 oligos comprising the artificial intron containing the polh promoter were synthesized and annealed. The 6,259-bp backbone fragment, the 977-bp fragment, and the annealed oligos were ligated to create the plasmid pAAV-inRC. The entire Rep coding sequence containing the artificial intron with the polh promoter was then amplified from pAAV-inRep by a PCR with forward primer 5′-gtgtgtatacccgccATGCCGGGGTTTTACGAGAT-3′ and reverse primer 5′-gcgcgcatgctcctTCAGAGAGAGTGTCCTCGAGC-3′ (BstZ17I and SphI sites are underlined and uppercases indicate the Rep coding sequence), digested with restriction endonucleases BstZ17I and SphI, and cloned into the SmaI and SphI sites of pFastBacDual (Invitrogen, Carlsbad, CA) to create pFBD-inRep. The same artificial intron was inserted in the Cap coding sequence between nucleotides 2,227 and 2,228 (GenBank accession no. AF043303). First, the plasmid pAAV-RC was digested with BamHI and EcoNI to isolate the backbone 4,969-bp fragment. The artificial intron was then amplified from pAAV-inRep with forward primer 5′-gcgcggatcctgttaagATGGCTGCC GATGGTTATCTTCCAGGtAAGtActccctAtcAGtGAtAGAG-3′ and reverse primer 5′-atatcgtctcgCTGAAACAATAGGAAGGGAGT GGAT-3′ (BamHI and BsmBI sites are underlined; uppercase indicates the Cap coding sequence, italics represent the artificial intron). The PCR product was then digested with BamHI and BsmBI. A second PCR fragment was amplified from pAAV-RC with forward primer 5′-aattcgtctc gTCAGATTGGCTCGAGGACACTCTCTCTGA-3′ and reverse primer 5′-TCCCGGAGCCGTCTTAACAG-3′ (BsmBI site is underlined), and digested with restriction enzymes BsmBI and EcoNI. The backbone fragment was ligated with the two PCR fragments to create pAAV-inCap. The entire Cap coding sequence comprising the artificial intron was then digested with BamHI and SnaBI and ligated to the BamHI and HindIII (blunted by Klenow) sites of the pFastBacDual plasmid to create the plasmid pFBD-inCap. Plasmids pFBD-Rep (containing AAV type 2 Rep78 and Rep52 in a palindromic head-to-tail configuration), pFBD-Cap (containing AAV type 2 VP1, VP2, and VP3 coding sequence with VP1 start codon mutated to ACG), and pFB-GFP were constructed as described earlier 17 and used as controls for this study. In order to construct pFBDCap6, the AAV6 capsid coding sequence was first amplified by PCR with forward primer 5′-cgcggatcctgttaagACGGCTGCCGACGGTTATCTA CCCGATTGGCTC-3′and reverse primer 5′-tcctctagagtcgaccgcTTAC AGGGGACGGGTGAGGT-3′ (BamHI and XbaI sites are underlined and uppercases indicate the AAV6 Cap coding sequence) and then cloned into the BamHI and XbaI sites of pFBD-Cap to replace the AAV2 capsid coding sequence. In order to construct pFBD-Cap8, the AAV8 capsid coding sequence was first amplified by PCR with the same forward primer as was used for AAV6, and reverse primer 5′-tcctctagagtcgaccgcTTACA GATTACGGGTGAGGT-3′ (XbaI site is underlined and uppercases indicate the AAV8 Cap coding sequence), and then cloned into the BamHI and XbaI sites of pFBD-Cap to replace the AAV2 capsid coding sequence. The same artificial intron as described above was then inserted into the Cap coding sequence of AAV type 8 between nucleotides 2,145 and 2,146 (GenBank accession no. NC_006261), AAV6 between nucleotides 2,232 and 2,233 (GenBank accession no. NC_001862), and AAV1 between nucleotides 2,247 and 2,248 (GenBank accession no. NC_002077). In order to construct pFBD-inCap8 and pFBD-inCap6, the artificial intron was amplified by PCR from pFBD-inCap with forward primer 5′-cccg gtaccgcatgctatgc-3′ and reverse primer 5′-ATGCCCTCAGAGAGGTT GTCCTCGAGCCAATctGAAAcAAt-3′ (EcoNI site is underlined and italics indicate the artificial intron sequence). The amplification product was digested with EcoNI and SphI, and the digested product was ligated to the EcoNI and SphI sites of pFBD-Cap8 and pFBD-Cap6 to create pFBD-inCap8 and pFBD-inCap6, respectively. In order to clone the artificial intron into the Cap coding sequence of AAV1, pFBD-inCap8 was digested with EcoNI and XbaI to remove the Cap coding sequence of AAV8. The Cap coding sequence of AAV1 was PCR-amplified from an AAV1 plasmid with forward primer 5′-GATTGGCTCGAGGACA ACCTCTCTG-3′ and reverse primer 5′-ggatcctctagagtcgaccgcTTA CAGGGGACGGGTAAGGT-3′ (XbaI site is underlined and uppercases indicate the AAV1 Cap coding sequence). The EcoNI-and XbaI-digested PCR fragment was ligated to the EcoNI-and XbaI-digested pFBD-inCap8 to create pFBD-inCap1.
Cell culture. HEK293 cells were maintained at 37 °C in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) containing 100 U/ml of penicillin and 100 mg/ml of streptomycin, and supplemented with 10% fetal calf serum (Sigma-Aldrich, St. Louis, MO). HepG2 cells were maintained at 37 °C in complete growth medium (American Type Culture Collection) containing 100 U/ml of penicillin and 100 mg/ml of streptomycin, and supplemented with 10% fetal calf serum. Spodoptera frugiperda Sf9 cells (Invitrogen, Carlsbad, CA) were maintained at 28 °C in Sf-900 II serum-free medium containing 100 U/ml of penicillin and 100 mg/ml of streptomycin (Invitrogen, Carlsbad, CA).
Generation of recombinant baculoviruses. Plasmids constructed as described earlier were used for transforming DH10Bac-competent cells to generate recombinant bacmids. These bacmids containing the target genes were used for generating recombinant baculoviruses in accordance with the manufacturer's protocol (Invitrogen, Carlsbad, CA), with minor modifications. Briefly, 2 ng of the plasmid DNA was used for transforming 20 μl of DH10Bac-competent cells. After 4 hours of incubation at 37 °C in 500 μl of SOC, 25 and 2.5 μl of the culture were plated separately in selection plates and incubated for 48 hours to allow white/blue colonies to form. Generally, three white colonies were picked for each construct and miniprep bacmid DNAs were prepared. The bacmid DNAs were used for transfecting Sf9 cells to generate recombinant baculoviruses.
Protein expression and Western blot. In order to obtain expression of the proteins, the Sf9 cells were infected by recombinant baculoviruses at 1 multiplicity of infection for 3 days at 28 °C and harvested by centrifugation at 3,000 rpm for 15 minutes. The cell pellets were lysed in NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA), boiled for 5 minutes, and sonicated for 10 seconds. The lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred onto polyvinylidene fluoride membrane, and the Rep78 and Rep52 were detected using monoclonal antibody clone 303.9 and Cap proteins VP1, VP2, and VP3 were detected using monoclonal antibody B1 clone (American Research Products, San Jose, CA).
Intron Splicing-mediated AAV Production in Insect Cells
AAV vector production and purification. Sf9 cells were grown at 28 °C to ~1 × 10 7 cells/ml in Sf-900 II serum-free medium containing 100 U/ml of penicillin and 100 μg/ml streptomycin, and then diluted to ~5 × 10 6 cells/ ml before infection. Triple infection was employed to produce AAV vectors. One multiplicity of infection each of Bac-inRep, Bac-GFP (or Bac-RFP), and Bac-inCap were used to infect the Sf9 cells at 28 °C for 3 days to produce AAV type 2 vectors. For AAV1, AAV6, and AAV8 production, Bac-inCap was simply substituted with Bac-inCap1, Bac-inCap6, and BacinCap8, respectively, in the triple infection. For comparison purposes, AAV vectors were also produced in insect cells using the artificial intron-less Rep and start codon-mutated (AUG to ACG) Cap coding sequences as described earlier. 17 After 3 days of infection, cell pellets were collected by centrifugation at 3,000 rpm for 15 minutes. The cell pellets were lysed as described 17 and cellular nucleic acids (DNA and RNA) were digested using benzonase (Sigma-Aldrich, St. Louis, MO). The cell lysates were cleared by centrifugation at 8,000 rpm for 30 minutes and then loaded onto a SW28 centrifuge tube containing a discontinuous gradient of 5 ml of 1.55 g/cc, and 10 ml of 1.32 g/cc of CsCl. After centrifugation at 28,000 rpm for 16 hours at 15 °C, the recombinant AAV-containing fraction was collected by puncturing the centrifuge tube with a syringe needle, and subjected to a second round of CsCl ultracentrifugation. The recombinant AAV-containing fraction was collected again by syringe needle. The AAV vectors were desalted into phosphate-buffered saline with a PD-10 desalting column (GE HealthCare, Piscataway, NJ). The production of AAV2 in HEK293 cells was performed using a triple-plasmid transfection method. 41 Vector titers were determined using quantitative real-time PCR assay in accordance with the manufacturer's protocol (Applied Biosystems, Foster City, CA).
In vitro transduction of HepG2 cells. Briefly, HepG2 cells were seeded at 1.5 × 10 5 cells/well in 24-well multiwells with 500-μl complete media/well 1 day before transduction. AAV vectors were serially diluted in serumfree media containing 20 μmol/l of etoposide (A.G. Scientific, San Diego, CA). After removing the old media, the cells were rinsed with serum-free media, and 500 μl/well of diluted AAV vectors were added. The cells were incubated at 37 °C for 48 hours and GFP-expressing cells or red fluorescent protein-expressing cells were recorded, and their relative infectivity was calculated.
